drugset / Trial / NCT02973646
Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is to observe the anti-HBV therapeutic effects of peginterferon alfa-2b in chronic hepatitis b patients with e antigen positive based on the detection of interferon gene mutation (IFNA2 p.Ala120Thr) and interferon receptor (IFNAR2) detection.
Timeline
- Start
- 2016-01
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 0.5 mg | — |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 80 ug | Other |
| Subject | Tenofovir | Small molecule | 300 mg | — |